伊芙美尔医疗 ICCC 深 沪
已收盘 10-31 16:00:00 美东时间
6.2393
+0.149
+2.45%
华盛通- 最 高6.275
- 今 开6.16
- 成交量 1.14万股
- 最 低 6.16
- 昨 收 6.09
- 总市值 5644.01万
- 52周最高 7.60
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 3.38
- 委 比 47.78%
- 总股本 904.59万
- 历史最高 13.20
- 量 比 0.37
- 振 幅 1.89%
- 历史最低 3.19
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ImmuCell announces preliminary sales results for Q3
ImmuCell Corporation (NASDAQ:ICCC) announced on Tuesday preliminary, unaudited sales results for the third quarter of 2025. Preliminary, Unaudited Total Sales Results: 2025 2024 ($ Decrease) $ I...
10-08 04:13
ImmuCell Announces Preliminary Q3 2025 Revenue Of $5.5M
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and
10-08 04:09
ImmuCell appoints Olivier te Boekhorst as CEO
ImmuCell (NASDAQ:ICCC) announced that it has selected Olivier te Boekhorst as its next President and CEO, anticipating a start date of November 1, 2025. The company said te Boekhorst is currently an o...
09-30 04:13
ImmuCell Selects Olivier Te Boekhorst As Its Next President, CEO, Expected Start Date November 1, 2025
PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven
09-30 04:06
ImmuCell Announces Selection of its Next President and CEO
ImmuCell Corporation announced the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. te Boekhorst, currently an Operating Partner at ARCHIMED and former CEO of SeqCenter, previously held leadership roles at IDEXX Laboratories, where he oversaw M&A activities and business growth. The Company’s current CEO, Michael F. Brigham, will serve as Special Advisor for two months to ensure a smooth transition. Imm...
09-29 20:05
【爱建电子】电子行业周报：Amazfit产业链迎来业绩拐点
（来源：爱建证券研究所） Amazfit产业链迎来业绩拐点 -爱建电子行业周报- 本报告发布于2025年08月20日 投资要点： 被动元件...
08-20 17:58
电话会总结 ｜ ImmuCell(ICCC)2025财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• **财务业绩**： - 2025年第二季度产品销售额同比增长18%，增加了97.2万美元；2025年上半年产品销售额同比增长14%，增加了180万美元；截至2025年6月30日的过去12个月产品销售额同比增长22%，增加了510万美元。 - 2025年第二季度调整后EBITDA为143万美元，而2024年同期为-11.9万美元；2025年上半年调整后EBITDA为370万美元，而2024年同期为-16.1万美元；截至2025年6月30日的过去12个月调整后EBITDA为530万美元，而2024年同期为-37万美元。 -
08-16 12:05
ImmuCell Reports Strong Sales Growth and Profitability
Immucell ( ($ICCC) ) has released its Q2 earnings. Here is a breakdown of the i...
08-16 11:55
ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite
Earnings Call Insights: ImmuCell Corporation (ICCC) Q2 2025 Management View Michael F. Brigham, President and CEO, stated that ImmuCell is “in the midst of a very positive transition,” having complete...
08-15 23:04
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
